ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0901

Scavenging of Isolevuglandins Attenuates Neutrophil Expansion and Aortic NETosis in Systemic Lupus Erythematosus

Jaya Krishnan1, Néstor de la Visitación1, Jonathan Williams1, Leslie Crofford2 and David Patrick3, 1Vanderbilt University Medical Center, Nashville, TN, 2Vanderbilt University Medical Center, Melbourne, AR, 3Department of Veterans Affairs, Nashville, TN

Meeting: ACR Convergence 2023

Keywords: Atherosclerosis, Cardiovascular, Mouse Models, Lupus, neutrophils, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (0899–0933) SLE – Etiology & Pathogenesis Poster

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Atherosclerosis and vascular inflammation are a cause of morbidity and mortality in systemic lupus erythematosus (SLE). Vascular NETosis is a driver of atherosclerosis and vascular inflammation. Isolevuglandins (IsoLGs) are lipid-aldehydes formed by peroxidation of arachidonic acid or prostaglandin-H2. IsoLGs are efficiently scavenged by 2-hydroxybenzylamine (2-HOBA). Treatment of SLE-prone B6.SLE123 mice with 2-HOBA attenuates systemic inflammation and reduces blood pressure. Additional studies have shown that isoLGs directly contribute to the formation of neutrophil extracellular traps (NETosis). We hypothesized that isoLGs contribute to neutrophil expansion and aortic NETosis in SLE-prone mice.

Methods: We treated 8-week-old female SLE prone B6.SLE123 mice with 1g/L 2-HOBA in the drinking water for 4-weeks. C57BL/6 mice were used as healthy controls. Spleens were harvested and splenocytes were submitted for single cell sequencing. Data were analyzed with Seurat v4.0.0 in R v4.0.4. NETosis in mouse tissue was measured by flow cytometry. Peripheral blood was obtained from a research subject with SLE that was recruited as part of the Memantine for the Treatment of Cognitive Impairment in Systemic Lupus Erythematosus clinical trial (IRB# 180256). To determine the role of isoLGs in NETosis, neutrophils were harvested from peripheral blood. Cells were seeded onto poly-L-lysine coated plates and incubated at 37°C for 2-hours in the presence of 200 μM ethyl-2-hydroxybenzylamine (ethy-2-HOBA), an isoLG scavenger with improved nuclear penetrance, or phosphate buffered saline as a control. Human NET formation was determined with immunofluorescence and quantified using the Imaris Cell Imaging Software (Oxford Instruments).

Results: Single cell sequencing revealed an increase in splenic neutrophils in B6.SLE123 mice compared to C57BL/6 controls. Treatment with 2HOBA attenuated this increase (C57BL/6 2.1%, B6.SLE123 3.8%, B6.SLE123+2HOBA 0.6% of total sequenced cells, N=3) (Figure 1A). Flow cytometry revealed an increase in circulating neutrophils in B6.SLE123 mice that was attenuated with 2HOBA (C57BL/6 6.5 ± 1.9%, B6.SLE123 10.2 ± 4.8%, B6.SLE123+2HOBA 6.2 ± 2.8% of CD45+ cells, N = 12-14)(Figure 1B). Aortic NETs were also increased in SLE prone mice which was attenuated following 2HOBA treatment (C57BL/6 19.2 ± 4.2%, B6.SLE123 28.1 ± 10.17%, B6.SLE123+2HOBA 19.7 ± 3.2% of neutrophils, N = 12-14)(Figure 1C). Human SLE subject neutrophils showed a reduction in total NET area after treatment with ethyl-2-HOBA (Control 4,415 ± 1238 µm2/field vs 2,215 ± 1372 µm2/field, n = 5, p = 0.029).

Conclusion: In a murine model of SLE, scavenging of isoLGs reduces neutrophils in secondary lymphoid tissue and peripheral blood. Additionally, we observe a reduction in vascular NETosis. Treatment of human neutrophils with an isoLG scavenger attenuates NET formation. These findings describe a role of isoLGs in SLE-associated NETosis and resultant vascular inflammation. Moreover, these findings suggest a potential role for isoLGs in NET-driven autoinflammation and vascular disease in SLE.

Supporting image 1

Figure 1. (A) UMAP of neutrophil clusters from cells isolated from spleens of C57BL/6, B6.SLE123, and B6.SLE123 mice treated with 2-HOBA following single cell sequencing. Significant expansion of neutrophils is present in SLE prone mice. This expansion is attenuated by 2-HOBA. (N=3) (B) Circulating neutrophils were quantified by flow cytometry. (C) NETs were quantified in aortas by flow cytometry. (N=12_14, data were compared with one-way ANOVA followed by Dunnett’s multiple comparison test).


Disclosures: J. Krishnan: None; N. de la Visitación: None; J. Williams: None; L. Crofford: None; D. Patrick: Metabolic Technologies, Inc., 9, 10.

To cite this abstract in AMA style:

Krishnan J, de la Visitación N, Williams J, Crofford L, Patrick D. Scavenging of Isolevuglandins Attenuates Neutrophil Expansion and Aortic NETosis in Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/scavenging-of-isolevuglandins-attenuates-neutrophil-expansion-and-aortic-netosis-in-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/scavenging-of-isolevuglandins-attenuates-neutrophil-expansion-and-aortic-netosis-in-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology